Medicure announces availability of ZYPITAMAG(TM) (pitavastatin) in the U.S.

About this update from Medicure Inc.

[{"type":"text","content":"\n\n\n\nMedicure announces availability of ZYPITAMAG™ (pitavastatin) in the U.S.\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\n\nCanada NewsWire\nWINNIPEG, May 1, 2018\n\n\n\nWINNIPEG, May 1, 2018 /CNW/ - Medicure (TSXV:MPH) today announced that pitavastatin magnesium (ZYPITAMAGTM) tablets are now available in retail pharmacies throughout the United States. ZYPITAMAGTM, a statin (HMG-CoA reductase inhibitor) medication approved by the U.S. Food and Drug Administration (FDA) in July 2017, is available in strengths of 1 mg, 2 mg and 4 mg. ZYPITAMAGTM is indicated for the treatment of patients with primary hyperlipidemia or mixed dyslipidemia as an adjunctive therapy to diet, to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). (Refer to the annexure appended below for the complete indication statement and important safety information.)\n\n\"Medicure is pleased to partner with Cadila Healthcare Ltd., India (Zydus group) and add ZYPITAMAGTM to its cardiovascular commercial operation. This partnership offers a cost effective pitavastatin alternative and fits with Medicure's mission of being a significant, value based, cardiovascular pharmaceutical company focused on the U.S. market,\" commented Medicure's President and CEO, Dr. Albert D. Friesen.\n\nAs previously announced Medicure entered into an agreement with Zydus to commercialize ZYPITAMAGTM for a term of seven years, with extensions to the term available. ZYPITAMAGTM was developed by Zydus via a 505(b)(2) New Drug Application procedure. Medicure is a U.S. pharmaceutical company and has a proven track-record of successful commercialization of products in the therapeutic segments of cardiovascular and metabolic diseases. As a part of this agreement, Zydus will hold the NDA and Medicure will be responsible for the sales and marketing of ZYPITAMAGTM. \n\nAbout Medicure \n\nMedicure is a pharmaceutical company focused on the development and commercialization of therapeutics f...

More updates from Medicure Inc.